drugset / Trial / NCT03164889
Clinical and Basic Research of ETV Plus GM-CSF in Chronic Hepatitis B Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Previous studies indicated that Granulocyte Macrophage-colony Stimulating Factor (GM-CSF) could improve survival rate in patients with acute liver failure and obtain higher HBsAg seroconversion rate when in combination with peg-interferon for chronic hepatitis B (CHB) patients. In this study, investigators will study the clinical effect of entecavir (ETV) plus GM-CSF in patients with CHB compared to ETV monotherapy.
Timeline
- Start
- 2017-01
- Primary completion
- 2018-01-01
- Completion
- 2021-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entecavir | Small molecule | 0.5 mg | Oral |
| Subject | sargramostim | Protein / enzyme biologic | 100 ug | Subcutaneous |